The Drug-Induced Respiratory Disease Website
See PMID 30075570. Review at PMID 28291095. Major risk is UAO, with consequent asphyxia. Can be followed by irreversible hypoxic brain damage/death. See also under VIIIg. May occur in isolation or accompany drug-induced anaphylaxis. Airway angioedema can be in the form of acute swelling of the lips, tongue, mouth floor, uvula, pharynx, larynx, glottis, subglottic area and/or upper trachea. This can cause acute upper airway obstruction (UAO) and asphyxia. May overlap with IVb. Expedient identification the airway by endoscopy and maintenance of airway patency are crucially important, as if the UAO progresses emergent risky tracheostomy can be required. Icatibant may alleviate all manifestations of drug-induced angioedema (PMID: 22936825). Rebound phenomenon can occur after an initial falsely reassuring period of improvement. NPPE (IIg) may occur as a secondary complication. Reviews and series at PMID 20447725, 20667117, 20922352, 22552531, 22936825, 22976464, 25059449. Angioedema can also involve the bowel wall in concomitance, causing abdominal pain or cramping or simulate an acute abdomen (PMID: 20376210, 21785085, 22867837)
Publications
Angioedema associated with aspirin and rofecoxib.
The Annals of pharmacotherapy 2005 May;39;944-8 — 2005 May — 944-8
Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2005 Jan;94;34-8 — 2005 Jan — 34-8
Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study.
British journal of clinical pharmacology 2003 Feb;55;166-74 — 2003 Feb — 166-74
Fatal haemorrhagic pulmonary oedema and associated angioedema after the ingestion of rofecoxib.
Postgraduate medical journal 2002 Jul;78;439-40 — 2002 Jul — 439-40